Tag: biosimilars vs generics
Biosimilars are billed differently than generics under Medicare Part B. Each has its own HCPCS code and payment rate based on its ASP plus 6% of the reference product’s price. This system encourages biosimilar entry but doesn’t strongly incentivize switching. Learn how billing works and why adoption remains low in the U.S.
Medications
Archives
Recent-posts
Unlock the Healing Potential of Northern Prickly Ash: The Dietary Supplement You Need Now
Feb, 7 2025
Counterfeit Medication Red Flags: What to Watch For
Dec, 1 2025
9 Alternatives to Levothyroxine
Apr, 7 2025
FDA Inspection of Generic Manufacturing Facilities: What to Expect
Mar, 5 2026
How to Keep a Medication List for Safer Care and Fewer Errors
Nov, 16 2025